News Alert—US-China Tariff War Implication for Healthcare Industry

News Alert—US-China Tariff War Implication for Healthcare Industry

Better Understand the Timeline of the Tariff War and What Triggered the Hostilities

RELEASE DATE
22-Nov-2019
REGION
North America
Deliverable Type
Market Research
Research Code: 9AB9-00-C2-00-00
SKU: HC03237-GL-MR_23760
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC03237-GL-MR_23760

News Alert—US-China Tariff War Implication for Healthcare Industry
Published on: 22-Nov-2019 | SKU: HC03237-GL-MR_23760

Need more details?

$1,500.00

$1,125.00save 25 %

DownloadLink
Need more details?

As the US-China Tariff War continues to escalate, the Transformational Healthcare Team at global research firm Frost & Sullivan has made available an insight analysis exploring the threats and opportunities for US businesses in China. The insight analysis also examines the timeline and causes of the tariff war and explores why medical technology (MedTech) is included in the United States’ new tariff policy.

The United States is the world’s largest medical technology importer, and China is its fourth-largest supplier. The tariff war is anticipated to create a ripple effect that will impact healthcare systems as costs rise. An unanswered question is who eventually absorbs the increase in costs of medical devices.

Frost & Sullivan's analysis suggests that manufacturers may absorb the costs for high-value medical devices, such as MRI and CT machines, passing some of those costs on to hospitals. For low-end products, especially consumables, customers will end up paying more.

Given the massive growth opportunity with China’s domestic market, the tariff war is not going to impact the planned investments of US companies in the Chinese MedTech industry. However, an uneven playing field favoring domestic companies over foreign ones can abate long-term optimism for the Chinese market. About 80% of US origin businesses operations in China indicated that the uneven playing field favoring domestic companies over foreign ones is making it increasingly difficult for US companies to compete in the Chinese market.

Tariffs at both points of the supply chain (in the United States and in China) run the risk of cost inflation for the companies that have manufacturing units in either country, which may eventually lead to an escalation in patient care costs across many countries. As a consequence of the US tariffs on China, other low-cost manufacturing destinations such as Malaysia, Vietnam, and Costa Rica will see a moderate increase in manufacturing activity with some companies expected to shift operations to these destinations. It is critical for US MedTech OEMs to evaluate the total cost of ownership as they examine alternative sourcing destinations. Additional regulatory considerations, such as FDA requirement for the supplemental submission for supplier change affecting changes to input could lead to delays of several months.

Frost & Sullivan finds that next year’s presidential election in the United States will be pivotal to the future of the ongoing US-China tariff war. Not surprisingly, healthcare is highly debated political issue. With the anticipated price transparency rules to take effect during 2020, dealing with the US-China tariff related inflation for the US healthcare industry will be a high-priority agenda for the newly elected president.

This Frost Perspective will help
• Better understand the timeline of the tariff war and what triggered the battle.
• Gain insight into why the United States included MedTech under the new tariff regime.
• Learn about the implications for the medical imaging, medical devices, and diagnostics industries and the ripple effect for healthcare systems.

Author: Kamaljit Behera

Key Findings

Research Scope

Top 5 Takeaways—Future Outlook for US-China MedTech Industries

Timeline of US-China Tariff War

What Triggered the Tariff Slugfest?

Why did the United States Include Medical Technology Under the New Tariff Regime?

Opportunities and Threats for US Businesses in China

Implication for the Medical Imaging Industry

Implication for Medical Devices and Diagnostics Industry

Implication for Medical Imaging and Technology Industry

Ripple Effect—Implication for Healthcare Systems?

Scenarios Analysis—Next Right-shoring Alternatives

Legal Disclaimer

US 301 Final List 1

US 301 Final List 1 (continued)

US 301 Final List 1 (continued)

US 301 Final List 3

US 301 Final List 4A

US 301 Final List 4B

List of Exhibits

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

As the US-China Tariff War continues to escalate, the Transformational Healthcare Team at global research firm Frost & Sullivan has made available an insight analysis exploring the threats and opportunities for US businesses in China. The insight analysis also examines the timeline and causes of the tariff war and explores why medical technology (MedTech) is included in the United States’ new tariff policy. The United States is the world’s largest medical technology importer, and China is its fourth-largest supplier. The tariff war is anticipated to create a ripple effect that will impact healthcare systems as costs rise. An unanswered question is who eventually absorbs the increase in costs of medical devices. Frost & Sullivan's analysis suggests that manufacturers may absorb the costs for high-value medical devices, such as MRI and CT machines, passing some of those costs on to hospitals. For low-end products, especially consumables, customers will end up paying more. Given the massive growth opportunity with China’s domestic market, the tariff war is not going to impact the planned investments of US companies in the Chinese MedTech industry. However, an uneven playing field favoring domestic companies over foreign ones can abate long-term optimism for the Chinese market. About 80% of US origin businesses operations in China indicated that the uneven playing field favoring domestic companies over foreign ones is making it increasingly difficult for US companies to compete in the Chinese market. Tariffs at both points of the supply chain (in the United States and in China) run the risk of cost inflation for the companies that have manufacturing units in either country, which may eventually lead to an escalation in patient care costs across many countries. As a consequence of the US tariffs on China, other low-cost manufacturing destinations such as Malaysia, Vietnam, and Costa Rica will see a moderate increase in manufacturing activity with some companies expected to shift operations to these destinations. It is critical for US MedTech OEMs to evaluate the total cost of ownership as they examine alternative sourcing destinations. Additional regulatory considerations, such as FDA requirement for the supplemental submission for supplier change affecting changes to input could lead to delays of several months. Frost & Sullivan finds that next year’s presidential election in the United States will be pivotal to the future of the ongoing US-China tariff war. Not surprisingly, healthcare is highly debated political issue. With the anticipated price transparency rules to take effect during 2020, dealing with the US-China tariff related inflation for the US healthcare industry will be a high-priority agenda for the newly elected president. This Frost Perspective will help • Better understand the timeline of the tariff war and what triggered the battle. • Gain insight into why the United States included MedTech under the new tariff regime. • Learn about the implications for the medical imaging, medical devices, and diagnostics industries and the ripple effect for healthcare systems. Author: Kamaljit Behera
More Information
Deliverable Type Market Research
No Index No
Podcast No
Author Kamaljit Behera
Industries Healthcare
WIP Number 9AB9-00-C2-00-00
Is Prebook No
GPS Codes 9600-B1,9A53-B1,9566-B1,9A47-B1,9A49-B1,9A4B-B1,9837-B1,9614-B1